Shehnaaz Suliman

Shehnaaz Suliman, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in 10x Genomics, Inc., Ultragenyx Pharmaceutical Inc. and Alector, Inc. Over a trading history stretching from 7 May 2021 to 22 September 2026, the count stands at 23 filings.

On the market, this insider has only sold: 9 sales, €525k in total. The totals do not cover 2 filings with an undisclosed amount. Besides market trades, the filings include 12 share grants and 2 option exercises. 2026 to date brings no purchases and 9 sales.

On 24 September 2026 came the latest disclosure, an open-market sale for €20k in 10x Genomics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.